FRX.CA
Fennec Pharmaceuticals, Inc.
Healthcare · Biotechnology · US
Sep 17, 2026, 11:30 UTC
Fennec Pharmaceuticals announced an oral presentation of detailed results from the investigator-initiated Phase 2 STS-J01 clinical study of Pedmark in Japan at SIOP 2026, with the primary endpoint met as ASHA-defined hearing loss occurred in 24.0% of patients versus the prespecified historical benchmark of 56.4% (P=0.001).
Source:Aug 11, 2026, 15:07 UTC
Adherex Technologies, operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period.